Abstract: Hyperuricemia is a recognized risk factor for cardiovascular diseases, particularly prevalent in individuals with hypertension. Addressing hyperuricemia holds the potential to mitigate the onset of hypertension. This investigation focused on exploring the uric acid-reducing capabilities of losartan in patients exhibiting stage 1 hypertension (as per JNC VIII) accompanied by asymptomatic hyperuricemia.